<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Ethambutol" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Ethambutol</book-part-id>
      <title-group>
        <title>Ethambutol</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>12</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Eteplirsen" document-type="chapter">Eteplirsen</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Ethionamide" document-type="chapter">Ethionamide</related-object>
    </book-part-meta>
    <body>
      <sec id="Ethambutol.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Ethambutol.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Ethambutol is a first line but adjunctive antituberculosis medication which is used only in combination with other agents such as isoniazid and rifampin. Ethambutol therapy has been associated with minor, transient and asymptomatic elevations in serum aminotransferase levels, and is a reported but rare cause of clinically apparent acute liver injury.</p>
        </sec>
        <sec id="Ethambutol.Background">
          <title>Background</title>
          <p>Ethambutol (eth am' bue tol) is a semisynthetic antibiotic which is bacteriostatic against Mycobacterium tuberculosis. Ethambutol interferes with the incorporation of mycolic acid into the mycobacterial cell wall, thus inhibiting its cell wall synthesis. Ethambutol has a broader spectrum of activity against mycobacterial species than isoniazid or rifampin and is therefore used largely in patients with suspected resistance or in atypical mycobacterial infections. Ethambutol is available in generic forms in tablets of 100 and 400 mg. The recommended dose is 15 mg/kg once daily in combination with other antituberculosis medications such as isoniazid, rifampin, pyrazinamide, and streptomycin. Higher doses are recommended for patients being retreated after a relapse. It is most typically given with pyrazinamide for the first two months of combination therapy of suspected resistant tuberculosis with isoniazid and rifampin, the latter two continuing for at least six months. Common side effects include gastrointestinal upset, nausea, dizziness, fever, and rash.</p>
          <p>The management of drug-resistant tuberculosis is challenging and should be under the direction of physicians with expertise in tuberculosis therapy and management of its side effects. Optimal regimens of therapy for tuberculosis are complex and change frequently. Regularly updated recommendations on use of drugs for tuberculosis, including indications, contraindications, warnings, dosages and monitoring recommendations are available at the Centers for Disease Control and Prevention website:&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/tb/publications/guidelines/Treatment.htm">https://www.cdc.gov/tb/publications/guidelines/Treatment.htm</ext-link>.</p>
        </sec>
        <sec id="Ethambutol.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Because ethambutol is almost always used in combination with isoniazid, rifampin or other antituberculosis agents, the frequency of serum aminotransferase elevations attributable to ethambutol alone cannot be estimated with any confidence. The addition of ethambutol to isoniazid, rifampin or pyrazinamide does not appear to increase the rate of transient ALT elevations during therapy. In addition, ethambutol is a rare cause of acute, symptomatic liver injury. Despite 50 years of use, ethambutol has been linked to clinically apparent liver injury in only a few case reports. In the best described instance (Case 1), the onset of symptoms was 2 months after starting combination antituberculosis therapy and, in contrast to liver injury due to isoniazid or pyrazinamide, the pattern of serum enzymes was distinctly cholestatic. The recurrence of liver injury upon rechallenge with ethambutol but not isoniazid made the attribution convincing. Other case reports have described liver injury occurring in the context of DRESS syndrome, arising within 2 to 6 weeks of starting antituberculosis therapy with fever, rash, eosinophilia and other organ involvement such as liver, kidney and lung. Several published instances have described recurrence of injury after rechallenge with ethambutol.</p>
          <p>Likelihood score: C (probable cause of clinically apparent liver injury often in the context of DRESS syndrome).</p>
        </sec>
        <sec id="Ethambutol.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The cause of liver injury due to ethambutol is not known, but is likely due to hypersensitivity.</p>
        </sec>
        <sec id="Ethambutol.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>Ethambutol is one of the few antituberculosis medications that is generally safe in the setting of liver disease. In the unlikely event of clinically apparent liver injury or allergic reaction to ethambutol, rechallenge, if necessary, should be done with caution. There does not appear to be cross sensitivity to liver injury with other antituberculosis medications.</p>
          <p>[First line medications used in the therapy of tuberculosis in the US include ethambutol, isoniazid, pyrazinamide, rifabutin, rifampin, and rifapentine. Second line medications include streptomycin, capreomycin, cycloserine, ethionamide, bedaquiline, pretomanid, fluoroquinolones such as levofloxacin and moxifloxacin, aminoglycosides such as amikacin, and para-aminosalicylic acid (PAS).]</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntituberculosisAgen" document-type="chapter">Antituberculosis Agents</related-object></p>
          <p>Other Drugs in the Class: <related-object link-type="booklink" source-id="livertox" document-id="Bedaquiline" document-type="chapter">Bedaquiline</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Capreomycin" document-type="chapter">Capreomycin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Cycloserine" document-type="chapter">Cycloserine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Ethionamide" document-type="chapter">Ethionamide</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Isoniazid" document-type="chapter">Isoniazid</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Pretomanid" document-type="chapter">Pretomanid</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Pyrazinamide" document-type="chapter">Pyrazinamide</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Rifabutin" document-type="chapter">Rifabutin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Rifampin" document-type="chapter">Rifampin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Rifapentine" document-type="chapter">Rifapentine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Streptomycin" document-type="chapter">Streptomycin</related-object></p>
        </sec>
      </sec>
      <sec id="Ethambutol.CASE_REPORT">
        <title>CASE REPORT</title>
        <sec id="Ethambutol.Case_1_Cholestatic_hepatitis">
          <title>Case 1. Cholestatic hepatitis caused by ethambutol.(<xref ref-type="bibr" rid="Ethambutol.REF.1">1</xref>)</title>
          <p>A 76 year old woman with pulmonary tuberculosis developed jaundice without abdominal pain or nausea two months after starting a course of isoniazid, streptomycin and ethambutol. She had no history of liver disease or excessive alcohol use. Liver tests were reported to be normal before starting therapy. Laboratory results showed a total serum bilirubin of 11.8 mg/dL with marked elevations in alkaline phosphatase [976 U/L] and gamma glutamyl transpeptidase [616 U/L] (Table). Tests for hepatitis A and B and for autoantibodies were negative. Ultrasound examination of the abdomen showed no evidence of biliary obstruction, and a liver biopsy showed intrahepatic cholestasis. On first presentation with jaundice, all medications were stopped and she began to improve. The initial diagnosis was isoniazid induced liver injury. Accordingly, therapy was reinstituted using ethambutol alone. Within 6 days, serum AST and alkaline phosphatase levels increased (Table). Ethambutol was stopped for 11 days and again restarted; however, serum alkaline phosphatase levels again rose, and ethambutol was permanently discontinued. After further improvements, isoniazid and streptomycin were restarted and subsequent treatment was well tolerated without recurrence of evidence of liver injury.</p>
          <sec id="Ethambutol.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Ethambutol.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Ethambutol.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Ethambutol.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Ethambutol (750 mg daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ethambutol.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Ethambutol.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Cholestatic (R=0.9)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ethambutol.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Ethambutol.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">3+ (jaundice, hospitalization)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ethambutol.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Ethambutol.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">2 months</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ethambutol.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Ethambutol.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">Interrupted by rechallenge, ultimately complete</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ethambutol.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Ethambutol.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Isoniazid, streptomycin</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Ethambutol.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Ethambutol.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">AST*<break/>(U/L)</th>
                    <th id="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P*<break/>(U/L)</th>
                    <th id="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin<break/>(mg/dL)</th>
                    <th id="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">8 weeks</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">264</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">976</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">11.8</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Therapy stopped</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">9 weeks</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">1 week</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">144</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">767</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1 hd_h_Ethambutol.Td_1_1_1_2 hd_h_Ethambutol.Td_1_1_1_3 hd_h_Ethambutol.Td_1_1_1_4 hd_h_Ethambutol.Td_1_1_1_5 hd_h_Ethambutol.Td_1_1_1_6" colspan="6" valign="top" align="center" scope="col" rowspan="1">Ethambutol restarted for 6 days</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">10 weeks</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">356</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">1225</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 days</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">280</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">1050</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 days</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">300</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">1020</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">11 weeks</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">7 days</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">260</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">950</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">10 days</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">76</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">812</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1 hd_h_Ethambutol.Td_1_1_1_2 hd_h_Ethambutol.Td_1_1_1_3 hd_h_Ethambutol.Td_1_1_1_4 hd_h_Ethambutol.Td_1_1_1_5 hd_h_Ethambutol.Td_1_1_1_6" colspan="6" valign="top" align="center" scope="col" rowspan="1">Ethambutol restarted for 4 days</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">12 weeks</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">228</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">1128</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">3 days</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">120</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">1020</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">6 days</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">110</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">1000</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">13 weeks</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">10 days</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">105</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">700</td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_1 hd_h_Ethambutol.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
                      <bold>Normal Values</bold>
                    </td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;40</bold>
                    </td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;130</bold>
                    </td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;1.2</bold>
                    </td>
                    <td headers="hd_h_Ethambutol.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="Ethambutol.TF.d.1">
                  <label>* </label>
                  <p>Some values estimated from Figure 1.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="Ethambutol.Comment">
            <title>Comment</title>
            <p>The role of ethambutol was defined by the response to rechallenge on two occasions during recovery and the later tolerance of isoniazid without worsening of blood test results. Also suggestive was the cholestatic pattern which is rare with isoniazid as well as the lack of viral hepatitis-like symptoms of nausea, abdominal pain and fatigue. Cholestatic hepatitis is marked by slow improvements in liver tests. The laboratory results were said to have &#x0201c;&#x02026;slowly returned to normal&#x02026;&#x0201d; but were not provided.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Ethambutol.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Ethambutol &#x02013; Generic, Myambutol&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Antituberculosis Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=ethambutol">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Ethambutol.CHEMICAL_FORMULA_AND_STRUCTUR">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Ethambutol.Te" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Ethambutol.Te_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Ethambutol.Te_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Ethambutol.Te_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Ethambutol.Te_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Ethambutol.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Ethambutol</td>
                <td headers="hd_h_Ethambutol.Te_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134970562">74-55-5</ext-link>
                </td>
                <td headers="hd_h_Ethambutol.Te_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C10-H24-N2-O2</td>
                <td headers="hd_h_Ethambutol.Te_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134970562" document-id-type="sid" document-type="summary" object-id="134970562" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Ethambutol.CITED_REFERENCES">
        <title>CITED REFERENCES</title>
        <ref-list id="Ethambutol.CITED_REFERENCES.reflist0">
          <ref id="Ethambutol.REF.1">
            <label>1</label>
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Gulliford</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Mackay</surname>
                  <given-names>AD</given-names>
                </name>
                <name name-style="western">
                  <surname>Prowse</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Cholestatic jaundice caused by ethambutol.</article-title>
              <source>Br Med J (Clin Res Ed)</source>
              <year>1986</year>
              <volume>292</volume>
              <fpage>866</fpage>
              <pub-id pub-id-type="pmid">3083914</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Ethambutol.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 24 December 2020</p>
        <p>Abbreviations: HIV, human immunodeficiency virus; DRESS, drug rash with eosinophilia and systemic symptoms; MAC, Mycobacterium avium complex; PAS, para-aminosalicylic acid.</p>
        <ref-list id="Ethambutol.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Ethambutol.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Antituberculosis agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 611-21.<annotation><p><italic toggle="yes">(Extensive review of hepatotoxicity of antituberculosis medications including ethambutol published in 1999; mentions a single case report of hepatotoxicity).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Ethambutol.REF.verma.2013">
            <mixed-citation publication-type="book">Verma S, Kaplowitz N. Hepatotoxicity of antituberculosis drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 483-504.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of antituberculosis drugs).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Ethambutol.REF.gumbo.2018">
            <mixed-citation publication-type="book">Gumbo T. Chemotherapy of tuberculosis, mycobacterium avium complex disease and leprosy. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1067-86.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Ethambutol.REF.lederman.1968.830">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lederman</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>FB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>PJ</given-names>
                </name>
              </person-group>
              <article-title>Exchange transfusion as treatment of acute hepatic failure due to antituberculosis drugs.</article-title>
              <source>Ann Intern Med</source>
              <year>1968</year>
              <volume>68</volume>
              <fpage>830</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(23 year old woman developed acute fever, rash and malaise 41 days after starting isoniazid, ethambutol and PAS for tuberculosis [bilirubin 3.0 rising to 30 mg/dL, ALT 850, Alk P 2 times ULN], accompanied by confusion and coma; treated with exchange transfusions and recovered; PAS was stopped promptly, but isoniazid continued for a period).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">5642965</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.hellstr_m.1969.69">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hellstr&#x000f6;m</surname>
                  <given-names>PE</given-names>
                </name>
                <name name-style="western">
                  <surname>Repo</surname>
                  <given-names>UK</given-names>
                </name>
              </person-group>
              <article-title>Capreomycin, ethambutol and rifampicin in apparently incurable pulmonary tuberculosis.</article-title>
              <source>Scand J Respir Dis Suppl</source>
              <year>1969</year>
              <volume>69</volume>
              <fpage>69</fpage>
              <lpage>74</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective analysis of 35 patients with severe, chronic or relapsing tuberculosis who were treated with capreomycin, ethambutol and rifampin; &#x0201c;liver damage&#x0201d; occurred in 49%, but was reversible in all; details not given).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4906377</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.repo.1970.72">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Repo</surname>
                  <given-names>UK</given-names>
                </name>
                <name name-style="western">
                  <surname>Hellstr&#x000f6;m</surname>
                  <given-names>PE</given-names>
                </name>
              </person-group>
              <article-title>Capreomycin and ethambutol in pulmonary tuberculosis. A preliminary report.</article-title>
              <source>Scand J Respir Dis Suppl.</source>
              <year>1970</year>
              <volume>72</volume>
              <fpage>72</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective analysis of 29 patients with severe tuberculosis treated with capreomycin and ethambutol with a third agent; &#x0201c;liver damage&#x0201d; occurred in 10%, but was reversible in all and consisted of mild elevations in ALT, AST and BSP retention).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">5273730</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.lees.1971.182">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lees</surname>
                  <given-names>AW</given-names>
                </name>
                <name name-style="western">
                  <surname>Allan</surname>
                  <given-names>GW</given-names>
                </name>
                <name name-style="western">
                  <surname>Smith</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Tyrrell</surname>
                  <given-names>WF</given-names>
                </name>
                <name name-style="western">
                  <surname>Fallon</surname>
                  <given-names>RJ</given-names>
                </name>
              </person-group>
              <article-title>Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy.</article-title>
              <source>Tubercle</source>
              <year>1971</year>
              <volume>52</volume>
              <fpage>182</fpage>
              <lpage>90</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 105 patients with active tuberculosis treated with isoniazid and rifampin, 22% had ALT and 13% bilirubin elevations, 8% skin rash and 3 a hypersensitivity reaction, two with jaundice [bilirubin 3.8 and 1.8 mg/dL; ALT 330 and 235 U/L], resolving on stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4255439</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.zierski.1973.132">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Zierski</surname>
                  <given-names>M.</given-names>
                </name>
              </person-group>
              <article-title>A trial of intermittent rifampin and ethambutol in retreatment regimens.</article-title>
              <source>Scand J Respir Dis Suppl</source>
              <year>1973</year>
              <volume>84</volume>
              <fpage>132</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(122 patients with tuberculosis were treated with rifampin and ethambutol daily for 2 months and then once or twice weekly for 1-2 years; abnormal liver tests occurred in 10% during daily regimen, 5% during long term treatment, but all changes were transient and mild not requiring discontinuation and attributed to rifampin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4522067</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.austerhoff.1974.1182">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Austerhoff</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Kindler</surname>
                  <given-names>U</given-names>
                </name>
                <name name-style="western">
                  <surname>Knop</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Knieriem</surname>
                  <given-names>HJ</given-names>
                </name>
              </person-group>
              <comment>[Liver toxicity of combined rifampicin-isoniazid-ethambutol medication]</comment>
              <source>Dtsch Med Wochenschr</source>
              <year>1974</year>
              <volume>99</volume>
              <fpage>1182</fpage>
              <comment>German.</comment>
              <pub-id pub-id-type="pmid">4835559</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.n_stase.1975.241">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>N&#x00103;stase</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>N&#x00103;stase</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Brener</surname>
                  <given-names>E.</given-names>
                </name>
              </person-group>
              <comment>[Side effects in strictly supervised treatment with rifampicin and ethambutol]</comment>
              <source>Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol.</source>
              <year>1975</year>
              <volume>24</volume>
              <fpage>241</fpage>
              <lpage>3</lpage>
              <comment>Romanian.</comment>
              <pub-id pub-id-type="pmid">174182</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.rossouw.1975.1">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Rossouw</surname>
                  <given-names>JE</given-names>
                </name>
                <name name-style="western">
                  <surname>Saunders</surname>
                  <given-names>SJ</given-names>
                </name>
              </person-group>
              <article-title>Hepatic complications of antituberculous therapy.</article-title>
              <source>Q J Med</source>
              <year>1975</year>
              <volume>44</volume>
              <fpage>1</fpage>
              <lpage>16</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective review identified 38 cases of hepatitis [~0.32%] due to antituberculosis therapy [Capetown, SA] 16 due to PAS, 12 to PAS with isoniazid, 3 isoniazid alone, 1 each of others including ethambutol; details of case attributed to ethambutol were not provided).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">50605</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.casteelsvan_daele.1975.739">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Casteels-Van Daele</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Igodt-Ameye</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Corbeel</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Eeckels</surname>
                  <given-names>R.</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity of rifampicin and isoniazid in children.</article-title>
              <source>J Pediatr</source>
              <year>1975</year>
              <volume>86</volume>
              <fpage>739</fpage>
              <lpage>41</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(13 year old boy developed symptoms 7 days and coma 11 days after starting isoniazid, rifampin and ethambutol for active tuberculosis [bilirubin 5.2 mg/dL, ALT 1500, Alk P 302, prothrombin index &#x0003c;10%], but recovering spontaneously and later treated with isoniazid without recurrence).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">1079531</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.girling.1978.13">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Girling</surname>
                  <given-names>DJ</given-names>
                </name>
              </person-group>
              <article-title>The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.</article-title>
              <source>Tubercle</source>
              <year>1978</year>
              <volume>59</volume>
              <fpage>13</fpage>
              <lpage>32</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(History and review of hepatotoxicity of first line antituberculosis medications).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">345572</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.chapoy.1978.637">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chapoy</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Ferracci</surname>
                  <given-names>JP</given-names>
                </name>
                <name name-style="western">
                  <surname>Mattei</surname>
                  <given-names>JF</given-names>
                </name>
                <name name-style="western">
                  <surname>Granjon</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Louchet</surname>
                  <given-names>E</given-names>
                </name>
              </person-group>
              <comment>[Severe hepatitis induced by chemotherapy with antitubercular agents in childhood. 2 cases]</comment>
              <source>Pediatrie</source>
              <year>1978</year>
              <volume>3</volume>
              <fpage>637</fpage>
              <lpage>45</lpage>
              <comment>French.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Two children, ages 4 and 12 years with onset of severe hepatitis 3 and 8 months after starting rifampin, isoniazid and PAS/prothionamide; one case was fatal and one resulted in cirrhosis; authors attributed injury to isoniazid).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">740454</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.addington.1979.782">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Addington</surname>
                  <given-names>WW</given-names>
                </name>
              </person-group>
              <article-title>The side effects and interactions of antituberculosis drugs.</article-title>
              <source>Chest</source>
              <year>1979</year>
              <volume>76</volume>
              <issue>6</issue>
              <supplement>Suppl</supplement>
              <fpage>782</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of side effects of antituberculosis medications states that isoniazid, rifampin and pyrazinamide are major causes of hepatotoxicity, whereas ethambutol rarely causes liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">510025</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.zierski.1980.41">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Zierski</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Bek</surname>
                  <given-names>E</given-names>
                </name>
              </person-group>
              <article-title>Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study.</article-title>
              <source>Tubercle</source>
              <year>1980</year>
              <volume>61</volume>
              <fpage>41</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 530 patients treated with 5 regimens [which included isoniazid, rifampin, streptomycin, pyrazinamide and ethambutol] for active tuberculosis and monitored monthly, 9% developed hepatic injury but usually without symptoms, ALT &#x0003e;250 U/L in 6 [1.1%], bilirubin rise in 7 [1.3%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6989067</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.bobrowitz.1980.117">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bobrowitz</surname>
                  <given-names>ID</given-names>
                </name>
              </person-group>
              <article-title>Ethambutol compared to rifampin in original treatment of pulmonary tuberculosis.</article-title>
              <source>Lung</source>
              <year>1980</year>
              <volume>157</volume>
              <fpage>117</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(218 patients treated with 3 regimens for tuberculosis; isoniazid with rifampin or ethambutol or both for 4 months followed by isoniazid for 20 months; 39 [18%] developed abnormal liver tests; 5 cases of hepatitis attributed to rifampin [2-8 weeks: overall 3.4%] and 3 to isoniazid [1-16 months: 1.3%], none to ethambutol).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7382540</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.snider.1981.727">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Snider</surname>
                  <given-names>D</given-names>
                  <suffix>Jr</suffix>
                </name>
                <name name-style="western">
                  <surname>Long</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Zierski</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Rogowski</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Bek</surname>
                  <given-names>E.</given-names>
                </name>
              </person-group>
              <article-title>Preliminary results of six-month regimens studied in the United States and in Poland.</article-title>
              <source>Chest</source>
              <year>1981</year>
              <volume>80</volume>
              <fpage>727</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Comparison of efficacy of 6-month vs 15-month regimens [the latter including ethambutol] for active tuberculosis in 672 patients, 9 relapses after short but none after long duration regimen; 21 [3.1%] had hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7307596</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.d_ssing.1982.205">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>D&#x000f8;ssing</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Andreasen</surname>
                  <given-names>PB</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs.</article-title>
              <source>Scand J Gastroenterol</source>
              <year>1982</year>
              <volume>17</volume>
              <fpage>205</fpage>
              <lpage>11</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 572 reports of drug induced liver injury from Denmark between 1968 and 1978, the most common causes were halothane [25%], chlorpromazine [9%], sulfonamides [9%], antituberculosis agents [7%], oxyphenisatin[4%], and methyldopa [2%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6982502</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.fiala.1983.1956">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Fiala</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>H&#x000e4;cki</surname>
                  <given-names>MA</given-names>
                </name>
                <name name-style="western">
                  <surname>Br&#x000e4;ndli</surname>
                  <given-names>O</given-names>
                </name>
              </person-group>
              <comment>[Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study]</comment>
              <source>Schweiz Med Wochenschr</source>
              <year>1983</year>
              <volume>113</volume>
              <fpage>1956</fpage>
              <lpage>9</lpage>
              <comment>German.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Controlled trial comparing pyrazinamide [n=52: &#x0003c;2 g/day] vs ethambutol [n=61] for first 2-3 months with isoniazid and rifampin for 9 months to treat active tuberculosis; hepatitis occurred in 5 on pyrazinamide and 2 on ethambutol, all in first month, 3 symptomatic, no deaths, most were &#x0003e;70 years of age).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6658432</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.cohen.1983.960">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Cohen</surname>
                  <given-names>CD</given-names>
                </name>
                <name name-style="western">
                  <surname>Sayed</surname>
                  <given-names>AR</given-names>
                </name>
                <name name-style="western">
                  <surname>Kirsch</surname>
                  <given-names>RE</given-names>
                </name>
              </person-group>
              <article-title>Hepatic complications of antituberculosis therapy revisited.</article-title>
              <source>S Afr Med J</source>
              <year>1983</year>
              <volume>63</volume>
              <fpage>960</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 5565 patients treated for tuberculosis in Capetown SA, 17 [0.3%] developed hepatitis, rate similar to that when PAS was used. Among 28 cases seen, 13 attributed to isoniazid, 16 pyrazinamide and 8 rifampin, mostly in combination; 2 deaths).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6857425</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.homberg.1985.722">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Homberg</surname>
                  <given-names>JC</given-names>
                </name>
                <name name-style="western">
                  <surname>Abuaf</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Helmy-Khalil</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Biour</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Poupon</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Islam</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Darnis</surname>
                  <given-names>F</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies.</article-title>
              <source>Hepatology</source>
              <year>1985</year>
              <volume>5</volume>
              <fpage>722</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of autoantibodies in 157 cases of drug induced liver injury; 3 categories&#x02013;drugs that are associated with and without antibodies to cytoplasmic organelles and those with specific antibodies; 4 cases of isoniazid hepatitis had no antibodies to nuclei, mitochondria, liver microsomes or smooth muscle).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4029887</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.gulliford.1986.866">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Gulliford</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Mackay</surname>
                  <given-names>AD</given-names>
                </name>
                <name name-style="western">
                  <surname>Prowse</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Cholestatic jaundice caused by ethambutol.</article-title>
              <source>Br Med J (Clin Res Ed)</source>
              <year>1986</year>
              <volume>292</volume>
              <fpage>866</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(78 year old woman developed jaundice 2 months after starting isoniazid, streptomycin and ethambutol [bilirubin 11.8 mg/dL, AST 264 U/L, Alk P 976 U/L] with negative rechallenge to isoniazid and positive rechallenge twice to ethambutol [Alk P rising from 767 to 1225 U/L, AST from 144 to 356 U/L], later tolerating isoniazid and streptomycin long term: Case 1).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3083914</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.van_aalderen.1987.290">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>van Aalderen</surname>
                  <given-names>WMC</given-names>
                </name>
                <name name-style="western">
                  <surname>Knoester</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Knol</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Fulminant hepatitis during treatment with rifampicin, pyrazinamide and ethambutol.</article-title>
              <source>Eur J Pediatr</source>
              <year>1987</year>
              <volume>146</volume>
              <fpage>290</fpage>
              <lpage>1</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(10 year old girl developed nausea and ALT elevations 2 weeks after starting isoniazid, rifampin, pyrazinamide and ethambutol resolving with stopping all drugs, but severe recurrence with fever, rash and fatal acute liver failure 6 weeks after adding pyrazinamide back to rifampin, ethambutol and kanamycin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3595648</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.donald.1987.741">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Donald</surname>
                  <given-names>PR</given-names>
                </name>
                <name name-style="western">
                  <surname>Schoeman</surname>
                  <given-names>JF</given-names>
                </name>
                <name name-style="western">
                  <surname>O&#x02019;Kennedy</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Hepatic toxicity during chemotherapy for severe tuberculosis meningitis.</article-title>
              <source>Am J Dis Child</source>
              <year>1987</year>
              <volume>141</volume>
              <fpage>741</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 33 children with tuberculous meningitis treated with 3-4 agents, liver test abnormalities were common [85%], but usually mild and transient, only one child developing jaundice who was also IgM anti-HAV positive and who later tolerated therapy without recurrence).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2884866</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.kasantikul.1989.56">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kasantikul</surname>
                  <given-names>V.</given-names>
                </name>
              </person-group>
              <article-title>Isoniazid-rifampicin-induced submassive hepatic necrosis.</article-title>
              <source>J Med Assoc Thai</source>
              <year>1989</year>
              <volume>72</volume>
              <fpage>56</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(58 year old woman developed nausea 3 weeks after starting isoniazid, rifampin and ethambutol and jaundice 3 weeks later [bilirubin 3.7 mg/dL, ALT 1590 U/L, Alk P 54 U/L, protime 72 sec], dying 5 days later).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2723568</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.wu.1990.502">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>JC</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>SD</given-names>
                </name>
                <name name-style="western">
                  <surname>Yeh</surname>
                  <given-names>PF</given-names>
                </name>
                <name name-style="western">
                  <surname>Chan</surname>
                  <given-names>CY</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>YJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>YS</given-names>
                </name>
                <name name-style="western">
                  <surname>Tsai</surname>
                  <given-names>YT</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Isoniazid-rifampin-induced hepatitis in hepatitis B carriers.</article-title>
              <source>Gastroenterology</source>
              <year>1990</year>
              <volume>98</volume>
              <fpage>502</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1783 patients with active tuberculosis treated with combination therapy [isoniazid, rifampin and ethambutol], 42 [2.3%] developed clinical hepatitis of whom 15 were HBsAg positive, fatality rate being 47% vs 4%, but no information on background features in the treated cohort or exclusion of reactivation of hepatitis B).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2295408</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.taneja.1990.278">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Taneja</surname>
                  <given-names>DP</given-names>
                </name>
                <name name-style="western">
                  <surname>Kaur</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <article-title>Study on hepatotoxicity and other side-effects of antituberculosis drugs.</article-title>
              <source>J Indian Med Assoc</source>
              <year>1990</year>
              <volume>88</volume>
              <fpage>278</fpage>
              <lpage>80</lpage>
              <pub-id pub-id-type="pmid">2090682</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.chiu.1990.358">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chiu</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Nussbaum</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Bozzette</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Tilles</surname>
                  <given-names>JG</given-names>
                </name>
                <name name-style="western">
                  <surname>Young</surname>
                  <given-names>LS</given-names>
                </name>
                <name name-style="western">
                  <surname>Leedom</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Heseltine</surname>
                  <given-names>PN</given-names>
                </name>
                <etal/>
                <collab>California Collaborative Treatment Group</collab>
              </person-group>
              <article-title>Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin.</article-title>
              <source>Ann Intern Med</source>
              <year>1990</year>
              <volume>113</volume>
              <fpage>358</fpage>
              <lpage>61</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(17 patients with AIDs and mycobacterium avium complex infection were treated with amikacin for 4 weeks and then 12 weeks of ciprofloxacin, ethambutol and rifampin; therapy stopped early in 2 patients for hepatitis, but no details given).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2382918</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.aziz.1990.290">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Aziz</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Agha</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Hassan</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Fairoz</surname>
                  <given-names>SA</given-names>
                </name>
                <name name-style="western">
                  <surname>Hassan</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity to different antituberculosis drug combinations.</article-title>
              <source>J Pak Med Assoc</source>
              <year>1990</year>
              <volume>40</volume>
              <fpage>290</fpage>
              <lpage>4</lpage>
              <pub-id pub-id-type="pmid">2126569</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.altman.1993.1212">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Altman</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Biour</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Grang&#x000e9;</surname>
                  <given-names>JD</given-names>
                </name>
              </person-group>
              <comment>[Hepatic toxicity of antitubercular agents. Role of different drugs. 199 cases]</comment>
              <source>Presse Med</source>
              <year>1993</year>
              <volume>22</volume>
              <fpage>1212</fpage>
              <lpage>6</lpage>
              <comment>French.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of 199 cases of hepatotoxicity from antituberculosis medications from literature [n=169] and French pharmacovigilance system [n=30]; overall mortality rate was 23%, rifampin cases had short latency [average 2 weeks] compared to isoniazid [11 weeks] and pyrazinamide [7 weeks]; one case attributed to ethambutol in the literature, none in their own series).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8248040</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.t_rkta_.1994.58">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>T&#x000fc;rkta&#x0015f;</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Unsal</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>T&#x000fc;lek</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Or&#x000fc;&#x000e7;</surname>
                  <given-names>O</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.</article-title>
              <source>Tuber Lung Dis</source>
              <year>1994</year>
              <volume>75</volume>
              <fpage>58</fpage>
              <lpage>60</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 705 Turkish adults with tuberculosis, 57 [8%] developed hepatitis with jaundice during therapy with isoniazid and rifampin; serologic testing showed hepatitis A in none, B in 6 and C in 4).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8161767</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.singh.1995.359">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Singh</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Arora</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Garg</surname>
                  <given-names>PK</given-names>
                </name>
                <name name-style="western">
                  <surname>Thakur</surname>
                  <given-names>VS</given-names>
                </name>
                <name name-style="western">
                  <surname>Pande</surname>
                  <given-names>JN</given-names>
                </name>
                <name name-style="western">
                  <surname>Tandon</surname>
                  <given-names>RK</given-names>
                </name>
              </person-group>
              <article-title>Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.</article-title>
              <source>Postgrad Med J</source>
              <year>1995</year>
              <volume>71</volume>
              <fpage>359</fpage>
              <lpage>62</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Case control study of 60 patients with liver injury due to antituberculosis medications and 60 controls from India identified lower BMI and pyrazinamide, but not age, sex, or acetylator status as risk factors).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7644398</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.singh.1996.211">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Singh</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Garg</surname>
                  <given-names>PK</given-names>
                </name>
                <name name-style="western">
                  <surname>Tandon</surname>
                  <given-names>RK</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy.</article-title>
              <source>J Clin Gastroenterol</source>
              <year>1996</year>
              <volume>22</volume>
              <fpage>211</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 72 patients with symptomatic liver injury due to antituberculosis medications, 12 had acute or subacute liver failure; among those who recovered, reinstitution of therapy was possible in 93%).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8724260</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.ormerod.1996.37">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ormerod</surname>
                  <given-names>LP</given-names>
                </name>
                <name name-style="western">
                  <surname>Horsfield</surname>
                  <given-names>N</given-names>
                </name>
              </person-group>
              <article-title>Frequency and type of reactions to antituberculosis drugs: observations in routine treatment.</article-title>
              <source>Tuber Lung Dis</source>
              <year>1996</year>
              <volume>77</volume>
              <fpage>37</fpage>
              <lpage>42</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1317 patients treated for active tuberculosis, hepatitis was attributed to rifampin in 1.4%, pyrazinamide in 1.2% and isoniazid in 0.3%, but none to ethambutol or streptomycin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8733412</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.ormerod.1996.111">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ormerod</surname>
                  <given-names>LP</given-names>
                </name>
                <name name-style="western">
                  <surname>Skinner</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Wales</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity of antituberculosis drugs.</article-title>
              <source>Thorax</source>
              <year>1996</year>
              <volume>51</volume>
              <fpage>111</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of hepatotoxicity of antituberculosis medications and recommendations on monitoring, with biochemical monitoring recommended only for patients with preexisting liver disease; in the UK between 1965-86, there were 243 reports of liver injury due to antituberculosis therapy and 45 fatalities).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8711637</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.pande.1996.132">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pande</surname>
                  <given-names>JN</given-names>
                </name>
                <name name-style="western">
                  <surname>Singh</surname>
                  <given-names>SP</given-names>
                </name>
                <name name-style="western">
                  <surname>Khilnani</surname>
                  <given-names>GC</given-names>
                </name>
                <name name-style="western">
                  <surname>Khilnani</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Tandom</surname>
                  <given-names>RK</given-names>
                </name>
              </person-group>
              <article-title>Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.</article-title>
              <source>Thorax</source>
              <year>1996</year>
              <volume>51</volume>
              <fpage>132</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Comparison of 86 patients with hepatitis due to antituberculosis therapy with 406 patients who tolerated therapy; risk factors were older age, history of high alcohol intake [20% vs 5%], more extensive disease [14% vs 3.5%], slow acetylator status [83% vs 64%] and use of pyrazinamide [63% vs 25%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8711642</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.d_ssing.1996.335">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>D&#x000f8;ssing</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Wilcke</surname>
                  <given-names>JT</given-names>
                </name>
                <name name-style="western">
                  <surname>Askgaard</surname>
                  <given-names>DS</given-names>
                </name>
                <name name-style="western">
                  <surname>Nybo</surname>
                  <given-names>B</given-names>
                </name>
              </person-group>
              <article-title>Liver injury during antituberculosis treatment: an 11-year study.</article-title>
              <source>Tuber Lung Dis</source>
              <year>1996</year>
              <volume>77</volume>
              <fpage>335</fpage>
              <lpage>40</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective chart review on 765 Danish patients treated for tuberculosis with 3 or 4 drugs for 6-9 months; 16% had AST elevations &#x0003e;2 times ULN usually in first month, but only 2% required modification of the regimen; 7 with jaundice, no fatalities; risk factors for hepatotoxicity were female sex, age and severe tuberculosis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8796249</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.durand.1996.394">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Durand</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Jebrak</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Pessayre</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Fournier</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Bernuau</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.</article-title>
              <source>Drug Saf</source>
              <year>1996</year>
              <volume>15</volume>
              <fpage>394</fpage>
              <lpage>405</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review and recommendations from France regarding monitoring of serum enzymes during therapy of tuberculosis; isoniazid may have direct hepatotoxicity because of dose relatedness and usual absence of recurrence on rechallenge; rifampin is rare cause of liver injury, usually with short latency period; pyrazinamide is clearly hepatotoxic at higher doses which should be kept to a minimum and for only 2 months).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8968694</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.garc_a_rodr_guez.1997.721">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Garc&#x000ed;a Rodr&#x000ed;guez</surname>
                  <given-names>LA</given-names>
                </name>
                <name name-style="western">
                  <surname>Ruig&#x000f3;mez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Jick</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom.</article-title>
              <source>Pharmacotherapy</source>
              <year>1997</year>
              <volume>17</volume>
              <fpage>721</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In epidemiological studies, antituberculosis medications have the highest relative risk for liver injury, hepatitis occurring in 0.4% of recipients).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">9250549</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.tahao_lu.2001.65">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Tahao&#x0011f;lu</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Ata&#x000e7;</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Sevim</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>T&#x000e4;r&#x000fc;n</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Yazicio&#x0011f;lu</surname>
                  <given-names>O</given-names>
                </name>
                <name name-style="western">
                  <surname>Horzum</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Gemci</surname>
                  <given-names>I</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>The management of anti-tuberculosis drug-induced hepatotoxicity.</article-title>
              <source>Int J Tuberc Lung Dis</source>
              <year>2001</year>
              <volume>5</volume>
              <fpage>65</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Description of 45 patients with hepatotoxicity from antituberculosis therapy, ages 15-76 years, ALT 42-897 U/L, bilirubin 0.2-7.0 mg/dL, arising in 6-102 days, with resolution in 4-58 days. No recurrence in those with gradual reintroduction of regimen without pyrazinamide compared to 6 cases [24%] in those with abrupt reintroduction).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">11263519</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.ohkawa.2002.220">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ohkawa</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Hashiguchi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Ohno</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Kiuchi</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Takahashi</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Kondo</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Echizen</surname>
                  <given-names>H</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.</article-title>
              <source>Clin Pharmacol Ther</source>
              <year>2002</year>
              <volume>72</volume>
              <fpage>220</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective analysis of 99 children who received therapy for tuberculosis, 8 developed hepatotoxicity; risk factors identified were young age and pyrazinamide exposure).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">12189369</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.hussain.2003.1226">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hussain</surname>
                  <given-names>Z</given-names>
                </name>
                <name name-style="western">
                  <surname>Kar</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Husain</surname>
                  <given-names>SA</given-names>
                </name>
              </person-group>
              <article-title>Antituberculosis drug-induced hepatitis: risk factors, prevention and management.</article-title>
              <source>Indian J Exp Biol</source>
              <year>2003</year>
              <volume>41</volume>
              <fpage>1226</fpage>
              <lpage>32</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review article on role of genetic polymorphisms of NAT2, CYP 2E1 and glutathione-S-transferase in hepatotoxicity of antituberculosis therapies).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15332488</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.elagroudy.2003.404">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>el-Agroudy</surname>
                  <given-names>AE</given-names>
                </name>
                <name name-style="western">
                  <surname>Refaie</surname>
                  <given-names>AF</given-names>
                </name>
                <name name-style="western">
                  <surname>Moussa</surname>
                  <given-names>OM</given-names>
                </name>
                <name name-style="western">
                  <surname>Ghoneim</surname>
                  <given-names>MA</given-names>
                </name>
              </person-group>
              <article-title>Tuberculosis in Egyptian kidney transplant recipients: study of clinical course and outcome.</article-title>
              <source>J Nephrol</source>
              <year>2003</year>
              <volume>16</volume>
              <fpage>404</fpage>
              <lpage>11</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1200 kidney transplant recipients, 45 [4%] developed tuberculosis usually after several years, all treated with isoniazid, rifampin and ethambutol; hepatotoxicity in 11 [25%], but severe in only 3).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">12832742</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.kurokawa.2003.596">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kurokawa</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Nakahigashi</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Teramachi</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Erythema multiforme-type drug eruption due to ethambutol with eosinophilia and liver dysfunction.</article-title>
              <source>Int J Antimicrob Agents</source>
              <year>2003</year>
              <volume>21</volume>
              <fpage>596</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(42 year old woman developed erythema multiforme 10 weeks after starting isoniazid, rifampin, pyrazinamide and ethambutol for pulmonary tuberculosis with 34% eosinophils, ALT 312 U/L and normal bilirubin resolving in 2 weeks on prednisone, positive rechallenge to ethambutol with rash; tolerated other agents).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">12791479</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.yee.2003.1472">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Yee</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Valiquette</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Pelletier</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Parisien</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Rocher</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Menzies</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <article-title>Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.</article-title>
              <source>Am J Respir Crit Care Med</source>
              <year>2003</year>
              <volume>167</volume>
              <fpage>1472</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 408 adult patients treated for tuberculosis, 37 [9%] had 46 serious adverse events including 12 instances of hepatitis [3%: 11 symptomatic, ALT &#x0003e;5 times ULN]; risk factors were age [hazard ratio 4.8-7.7], female sex [2.2] and Asian birthplace [2.2]; hepatitis arose in 2% on pyrazinamide and 1% on isoniazid).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">12569078</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.fern_ndezvillar.2004.1499">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Fern&#x000e1;ndez-Villar</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Sope&#x000f1;a</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Fern&#x000e1;ndez-Villar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>V&#x000e1;zquez-Gallardo</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Ulloa</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Leiro</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Mosteiro</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.</article-title>
              <source>Int J Tuberc Lung Dis</source>
              <year>2004</year>
              <volume>8</volume>
              <fpage>1499</fpage>
              <lpage>505</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 471 patients receiving antituberculosis therapy, 56 [12%] developed ALT elevations above 3 times ULN, 16 [3.4%] and symptoms and 5 [1%] were jaundiced; no deaths. Rates of hepatotoxicity higher in patients with risk factors than without [18.2% vs 5.6%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15636498</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.russo.2004.1018">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Russo</surname>
                  <given-names>MW</given-names>
                </name>
                <name name-style="western">
                  <surname>Galanko</surname>
                  <given-names>JA</given-names>
                </name>
                <name name-style="western">
                  <surname>Shrestha</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Fried</surname>
                  <given-names>MW</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>P</given-names>
                </name>
              </person-group>
              <article-title>Liver transplantation for acute liver failure from drug-induced liver injury in the United States.</article-title>
              <source>Liver Transpl</source>
              <year>2004</year>
              <volume>10</volume>
              <fpage>1018</fpage>
              <lpage>23</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among ~50,000 liver transplants reported to UNOS between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, 124 for acetaminophen and 137 for other toxins, the most common being isoniazid [24], propylthiouracil [13], phenytoin [10], valproate [10], amanita [9], nitrofurantoin [7], herbals [7], ketoconazole [6], disulfiram [6], troglitazone [4] and 28 others).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15390328</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.marra.2004.905">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Marra</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Cox</surname>
                  <given-names>VC</given-names>
                </name>
                <name name-style="western">
                  <surname>FitzGerald</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Moadebi</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Elwood</surname>
                  <given-names>RK</given-names>
                </name>
              </person-group>
              <article-title>Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant.</article-title>
              <source>Int J Tuberc Lung Dis</source>
              <year>2004</year>
              <volume>8</volume>
              <fpage>905</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(28 year old woman with tuberculous lymphadenitis treated with isoniazid, rifampin, ethambutol and pyrazinamide, switching to ciprofloxacin with pyrazinamide and ethambutol when resistance testing was done; four days later she developed fever, rash and fatigue [bilirubin normal, ALT 285 U/L, Alk P normal], but then worsened [bilirubin 15.2 mg/dL, ALT 1165 U/L, Alk P 141 U/L] and ultimately required liver transplant, yet later was treated successfully with levofloxacin, amikacin and streptomycin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15260286</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.younossian.2005.462">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Younossian</surname>
                  <given-names>AB</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochat</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Ketterer</surname>
                  <given-names>JP</given-names>
                </name>
                <name name-style="western">
                  <surname>Wacker</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Janssens</surname>
                  <given-names>JP</given-names>
                </name>
              </person-group>
              <article-title>High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.</article-title>
              <source>Eur Respir J</source>
              <year>2005</year>
              <volume>26</volume>
              <fpage>462</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 12 persons treated with pyrazinamide and ethambutol for latent tuberculosis and contact with a patient with multidrug resistant disease, 7 developed liver injury [ALT 82-1338 U/L], after 87 to 247 days, 3 with symptoms, no mention of bilirubin levels).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16135729</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.andrade.2005.512">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Andrade</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Lucena</surname>
                  <given-names>MI</given-names>
                </name>
                <name name-style="western">
                  <surname>Fernandez</surname>
                  <given-names>MC</given-names>
                </name>
                <name name-style="western">
                  <surname>Pelaez</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Pachkoria</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Garcia-Ruiz</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Garcia-Munoz</surname>
                  <given-names>B</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period.</article-title>
              <source>Gastroenterology</source>
              <year>2005</year>
              <volume>129</volume>
              <fpage>512</fpage>
              <lpage>21</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 446 cases of drug induced liver injury collected in Spain between 1984-2004, isoniazid [with or without rifampin and pyrazinamide] was implicated in 22 cases [5%: ranking 3rd] and was fatal or required liver transplant in 5 [ranking first]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16083708</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.lee.2005.1304">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>BH</given-names>
                </name>
                <name name-style="western">
                  <surname>Koh</surname>
                  <given-names>WJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Choi</surname>
                  <given-names>MS</given-names>
                </name>
                <name name-style="western">
                  <surname>Suh</surname>
                  <given-names>GY</given-names>
                </name>
                <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>MP</given-names>
                </name>
                <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Kwon</surname>
                  <given-names>OJ</given-names>
                </name>
              </person-group>
              <article-title>Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.</article-title>
              <source>Chest</source>
              <year>2005</year>
              <volume>127</volume>
              <fpage>1304</fpage>
              <lpage>11</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective case control study of 110 HBsAg carriers and 97 controls from Korea who received 3-4 drug antituberculosis therapy; any ALT elevations occurred in 34% of carriers vs 20% of controls and were &#x0003e;3 times ULN in 8% vs 4%; no risk factors identified, most tolerated reintroduction of therapy without pyrazinamide).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15821209</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.yew.2006.699">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Yew</surname>
                  <given-names>WW</given-names>
                </name>
                <name name-style="western">
                  <surname>Leung</surname>
                  <given-names>CC</given-names>
                </name>
              </person-group>
              <article-title>Antituberculosis drugs and hepatotoxicity.</article-title>
              <source>Respirology</source>
              <year>2006</year>
              <volume>11</volume>
              <fpage>699</fpage>
              <lpage>707</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of incidence, causes, risk factors and management of hepatotoxicity of antituberculosis medications).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17052297</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.saukkonen.2006.935">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Saukkonen</surname>
                  <given-names>JJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Cohn</surname>
                  <given-names>DL</given-names>
                </name>
                <name name-style="western">
                  <surname>Jasmer</surname>
                  <given-names>RM</given-names>
                </name>
                <name name-style="western">
                  <surname>Schenker</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Jereb</surname>
                  <given-names>JA</given-names>
                </name>
                <name name-style="western">
                  <surname>Nolan</surname>
                  <given-names>CM</given-names>
                </name>
                <name name-style="western">
                  <surname>Peloquin</surname>
                  <given-names>CA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy.</article-title>
              <source>Am J Respir Crit Care Med</source>
              <year>2006</year>
              <volume>174</volume>
              <fpage>935</fpage>
              <lpage>52</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(American Thoracic Society recommendations regarding hepatotoxicity of antituberculosis therapy; for latent infection, 9 months of isoniazid is first choice and 4 months of rifampin second; clinical monitoring is recommend for all patients and biochemical monitoring for those at high risk and possibly the elderly [ALT values at 1, 3 and 6 months or every 1-2 months]; hold therapy if ALT above 5 times ULN or if symptoms are present and ALT is above 3 times ULN; mentions that there has been only one report of ethambutol hepatoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17021358</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.forget.2006.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Forget</surname>
                  <given-names>EJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Menzies</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <article-title>Adverse reactions to first-line antituberculosis drugs.</article-title>
              <source>Expert Opin Drug Saf</source>
              <year>2006</year>
              <volume>5</volume>
              <fpage>231</fpage>
              <lpage>49</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of side effects including hepatotoxicity of isoniazid, asymptomatic elevations in ALT levels occur in 10-22% of patients, but 80% of these resolve even with continuing therapy; overall rate of hepatotoxicity is 0.9%, mortality 0.04%).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16503745</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.shigeto.2007.467">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Shigeto</surname>
                  <given-names>E</given-names>
                </name>
                <collab>Committee for Treatment Japanese Society for Tuberculosis</collab>
              </person-group>
              <comment>[Survey of anti-tuberculosis drug-induced severe liver injury in Japan]</comment>
              <source>Kekkaku</source>
              <year>2007</year>
              <volume>82</volume>
              <fpage>467</fpage>
              <lpage>73</lpage>
              <comment>Japanese.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Abstract: Survey questionnaire to 114 Japanese hospitals identified 70 cases of severe liver injury and 8 deaths due to antituberculosis therapy between 1994-2003).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17564126</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.idilman.2006.1427">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Idilman</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Ersoz</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Coban</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Kumbasar</surname>
                  <given-names>O</given-names>
                </name>
                <name name-style="western">
                  <surname>Bozkaya</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy.</article-title>
              <source>Liver Transpl</source>
              <year>2006</year>
              <volume>12</volume>
              <fpage>1427</fpage>
              <lpage>30</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(19 year old woman with peritoneal tuberculosis developed jaundice 4 days after starting isoniazid, rifampin, ethambutol and pyrazinamide [bilirubin 10.5 mg/dL, ALT 1332 U/L, protime 71 sec], undergoing living donor liver transplantation within 2 days and afterwards treated with streptomycin, ethambutol and cycloserine with no recurrence).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16933231</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.bj_rnsson.2007.1411">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Kalaitzakis</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Olsson</surname>
                  <given-names>R</given-names>
                </name>
              </person-group>
              <article-title>The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury.</article-title>
              <source>Aliment Pharmacol Ther</source>
              <year>2007</year>
              <volume>25</volume>
              <fpage>1411</fpage>
              <lpage>21</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of 570 case reports of drug induced liver injury suggested that eosinophilia was associated with a favorable prognosis, lower peak bilirubin and lower fatality rate).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17539980</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.sabat_.2007.1401">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sabat&#x000e9;</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Ib&#x000e1;&#x000f1;ez</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>P&#x000e9;rez</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Vidal</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Buti</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Xiol</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Mas</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Risk of acute liver injury associated with the use of drugs: a multicentre population survey.</article-title>
              <source>Aliment Pharmacol Ther</source>
              <year>2007</year>
              <volume>25</volume>
              <fpage>1401</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Population based survey of 126 cases of acute liver injury due to drugs between 1993-1999 in Spain calculated relative risk of injury compared to the general population to be 1300 with use of triple therapy [isoniazid, rifampin and pyrazinamide] and 154 for isoniazid alone, ranking first and third).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17539979</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.kwon.2007.803">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kwon</surname>
                  <given-names>YS</given-names>
                </name>
                <name name-style="western">
                  <surname>Koh</surname>
                  <given-names>WJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Suh</surname>
                  <given-names>GY</given-names>
                </name>
                <name name-style="western">
                  <surname>Chung</surname>
                  <given-names>MP</given-names>
                </name>
                <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Kwon</surname>
                  <given-names>OJ</given-names>
                </name>
              </person-group>
              <article-title>Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy.</article-title>
              <source>Chest</source>
              <year>2007</year>
              <volume>131</volume>
              <fpage>803</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective analysis of 54 patients with HCV infection and 97 controls receiving therapy for active tuberculosis; ALT &#x0003e;3 times ULN occurred in 13% of HCV infected vs 4% of controls; none died or required hospitalization).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17356096</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.aouam.2007.253">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Aouam</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Chaabane</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Loussa&#x000ef;ef</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Ben Romdhane</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Boughattas</surname>
                  <given-names>NA</given-names>
                </name>
                <name name-style="western">
                  <surname>Chakroun</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <comment>[Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management]</comment>
              <source>Med Mal Infect</source>
              <year>2007</year>
              <volume>37</volume>
              <fpage>253</fpage>
              <lpage>61</lpage>
              <comment>French.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of toxicities of antituberculosis agents; ethambutol can cause optic neuritis, allergic reactions, and rash; liver injury is rare except for mild hyperbilirubinemia not requiring dose adjustment).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17336011</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.huang.2007.1">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>YS</given-names>
                </name>
              </person-group>
              <article-title>Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury.</article-title>
              <source>Expert Opin Drug Metab Toxicol</source>
              <year>2007</year>
              <volume>3</volume>
              <fpage>1</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Two gene variants have been linked to an increased risk of hepatotoxicity of antituberculosis medications; NAT2 and CYP 2E1, but the associations require further confirmation).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17269890</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.marzuki.2008.688">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Marzuki</surname>
                  <given-names>OA</given-names>
                </name>
                <name name-style="western">
                  <surname>Fauzi</surname>
                  <given-names>AR</given-names>
                </name>
                <name name-style="western">
                  <surname>Ayoub</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Kamarul Imran</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia.</article-title>
              <source>Singapore Med J</source>
              <year>2008</year>
              <volume>49</volume>
              <fpage>688</fpage>
              <lpage>93</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 473 patients treated for tuberculosis, 46 [9.7%] developed ALT elevations above 3 times ULN; in a case control analysis, concurrent HIV infection was a risk factor).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18830542</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>PB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davern</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Serrano</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochon</surname>
                  <given-names>J</given-names>
                </name>
                <collab>Drug Induced Liver Injury Network (DILIN)</collab>
              </person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, isoniazid was implicated in 15 cases [5%: ranking 3rd] being the only agent implicated in 13 cases and implicated with other agents in two cases; but no case was linked to ethambutol).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.kaneko.2008.13">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kaneko</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Nagayama</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Kawabe</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Shimada</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Suzuki</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Kunogi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Matsui</surname>
                  <given-names>Y</given-names>
                </name>
                <etal/>
              </person-group>
              <comment>[Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis]</comment>
              <source>Kekkaku</source>
              <year>2008</year>
              <volume>83</volume>
              <fpage>13</fpage>
              <lpage>9</lpage>
              <comment>Japanese.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Abstract: reports on substantial higher frequency of ALT elevations in patients with chronic hepatitis C associated with pyrazinamide therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18283910</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.tostmann.2008.192">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Tostmann</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Boeree</surname>
                  <given-names>MJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Aarnoutse</surname>
                  <given-names>RE</given-names>
                </name>
                <name name-style="western">
                  <surname>de Lange</surname>
                  <given-names>WC</given-names>
                </name>
                <name name-style="western">
                  <surname>van der Ven</surname>
                  <given-names>AJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Dekhuijzen</surname>
                  <given-names>R</given-names>
                </name>
              </person-group>
              <article-title>Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.</article-title>
              <source>J Gastroenterol Hepatol</source>
              <year>2008</year>
              <volume>23</volume>
              <fpage>192</fpage>
              <lpage>202</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of incidence, pathogenesis, clinical course, risk factors and management of drug induced liver disease due to antituberculosis medications).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17995946</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.lee.2008.521">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>JH</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>HK</given-names>
                </name>
                <name name-style="western">
                  <surname>Heo</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>TO</given-names>
                </name>
                <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>GH</given-names>
                </name>
                <name name-style="western">
                  <surname>Kang</surname>
                  <given-names>DH</given-names>
                </name>
                <name name-style="western">
                  <surname>Song</surname>
                  <given-names>GA</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs.</article-title>
              <source>J Korean Med Sci</source>
              <year>2008</year>
              <volume>23</volume>
              <fpage>521</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(29 year old woman developed fever, rash, eosinophilia and jaundice 6 weeks after starting celecoxib and 5 weeks after starting antituberculosis therapy with isoniazid, rifampin, pyrazinamide and ethambutol [bilirubin 3.6 mg/dL, ALT 327 U/L, Alk P 788 U/L, eosinophils 12%], improving upon stopping and recurring upon restarting with severe myositis and pneumonitis, treated with prednisone and ultimately resolved, but had positive patch tests to celecoxib and ethambutol).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18583892</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.ferrajolo.2010.721">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ferrajolo</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Capuano</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Verhamme</surname>
                  <given-names>KM</given-names>
                </name>
                <name name-style="western">
                  <surname>Schuemie</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Rossi</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Stricker</surname>
                  <given-names>BH</given-names>
                </name>
                <name name-style="western">
                  <surname>Sturkenboom</surname>
                  <given-names>MC</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.</article-title>
              <source>Br J Clin Pharmacol</source>
              <year>2010</year>
              <volume>70</volume>
              <fpage>721</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, 2 antituberculosis agents were among the top 40 cases, including isoniazid [24th, 47 cases] and rifampin [35th, 37 cases], but not ethambutol).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21039766</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Reuben</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Koch</surname>
                  <given-names>DG</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>WM</given-names>
                </name>
                <collab>Acute Liver Failure Study Group</collab>
              </person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury and 25 to antituberculosis agents, including 15 to isoniazid alone [ranking first], 6 to isoniazid combined with other agents, 3 to rifampin and pyrazinamide and 1 to dapsone, but no cases were attributed even secondarily to ethambutol).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.devarbhavi.2010.2396">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Devarbhavi</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Dierkhising</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Kremers</surname>
                  <given-names>WK</given-names>
                </name>
                <name name-style="western">
                  <surname>Sandeep</surname>
                  <given-names>MS</given-names>
                </name>
                <name name-style="western">
                  <surname>Karanth</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Adarsh</surname>
                  <given-names>CK</given-names>
                </name>
              </person-group>
              <article-title>Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality.</article-title>
              <source>Am J Gastroenterol</source>
              <year>2010</year>
              <volume>105</volume>
              <fpage>2396</fpage>
              <lpage>404</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 313 cases of drug induced liver injury seen between 1997 and 2008 at a large hospital in Bangalore, India, 181 [58%] were attributed to antituberculosis agents which accounted for 39 of 54 [72%] fatal cases; ethambutol not specifically mentioned).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20648003</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.palmero.2013.76">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Palmero</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Castagnino</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Musella</surname>
                  <given-names>RM</given-names>
                </name>
                <name name-style="western">
                  <surname>Mosca</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Gonz&#x000e1;lez Montaner</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>de Casado</surname>
                  <given-names>GC</given-names>
                </name>
              </person-group>
              <article-title>Difficult clinical management of anti-tuberculosis DRESS syndrome.</article-title>
              <source>Int J Tuberc Lung Dis</source>
              <year>2013</year>
              <volume>17</volume>
              <fpage>76</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of 11 patients with DRESS syndrome attributed to antituberculosis medications, one was attributed to ethambutol and isoniazid and one to ethambutol with isoniazid, rifampin and pyrazinamide).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23114284</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.li.2013.859">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Li</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Long</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Hu</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>Y.</given-names>
                </name>
              </person-group>
              <article-title>GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.</article-title>
              <source>Eur J Clin Microbiol Infect Dis</source>
              <year>2013</year>
              <volume>32</volume>
              <fpage>859</fpage>
              <lpage>68</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Metaanalysis of studies on the association of tuberculosis drug associated liver injury and polymorphisms of the glutathione S-transferase genes found weak associations only).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23377313</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.shin.2014.347">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Shin</surname>
                  <given-names>HJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>HS</given-names>
                </name>
                <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>YI</given-names>
                </name>
                <name name-style="western">
                  <surname>Lim</surname>
                  <given-names>SC</given-names>
                </name>
                <name name-style="western">
                  <surname>Jung</surname>
                  <given-names>JP</given-names>
                </name>
                <name name-style="western">
                  <surname>Ko</surname>
                  <given-names>YC</given-names>
                </name>
                <name name-style="western">
                  <surname>Kwon</surname>
                  <given-names>YS</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.</article-title>
              <source>Int J Tuberc Lung Dis</source>
              <year>2014</year>
              <volume>18</volume>
              <fpage>347</fpage>
              <lpage>51</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective analysis of 197 patients treated for tuberculosis found serum enzyme elevations [72% vs 46%] and drug induced liver injury [8% vs 2.7%] more common in 50 patients who had cirrhosis than in 147 without, but all patients recovered; specific agents responsible for injury were not identified).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24670574</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.kaswala.2013.83">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kaswala</surname>
                  <given-names>DH</given-names>
                </name>
              </person-group>
              <article-title>Drug rash with eosinophilia and systemic symptoms syndrome due to anti-TB medication.</article-title>
              <source>J Family Med Prim Care</source>
              <year>2013</year>
              <volume>2</volume>
              <fpage>83</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(68 year old man with tuberculosis developed rash, eosinophilia and serum aminotransferase elevations [details not given] 8 weeks after starting isoniazid, rifampin, pyrazinamide and ethambutol, resolving within a month of stopping and with prednisone therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24479051</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.li.2013.859_1">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Li</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Long</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Hu</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhou</surname>
                  <given-names>Y.</given-names>
                </name>
              </person-group>
              <article-title>GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis.</article-title>
              <source>Eur J Clin Microbiol Infect Dis</source>
              <year>2013</year>
              <volume>32</volume>
              <fpage>859</fpage>
              <lpage>68</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Metaanalysis of studies on the association of tuberculosis drug associated liver injury and polymorphisms of the glutathione S-transferase genes found weak associations only).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23377313</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.kumar.2014.5760">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kumar</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Kedarisetty</surname>
                  <given-names>CK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kumar</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Khillan</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Sarin</surname>
                  <given-names>SK</given-names>
                </name>
              </person-group>
              <article-title>Antitubercular therapy in patients with cirrhosis: challenges and options.</article-title>
              <source>World J Gastroenterol</source>
              <year>2014</year>
              <volume>20</volume>
              <fpage>5760</fpage>
              <lpage>72</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the frequency, pathogenesis and management of hepatotoxicity of antituberculosis therapy in patients with preexisting cirrhosis, who appear to have an increased risk of liver injury from these agents as well as an increased risk of severe outcomes).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24914337</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.huang.2014.169">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>YS</given-names>
                </name>
              </person-group>
              <article-title>Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury.</article-title>
              <source>J Chin Med Assoc</source>
              <year>2014</year>
              <volume>77</volume>
              <fpage>169</fpage>
              <lpage>73</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Critical review of studies on genetic variations associated with antituberculosis drug induced liver injury focusing on N-acetyltransferase (NAT), CYP 2E1, glutathione S transferase and manganese superoxide dismutase, the strongest association being with NAT and slow acetylator status).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24593909</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, 13 [7%] due to antituberculosis agents including 6 to isoniazid, 1 to pyrazinamide, 1 to rifampin and 5 to combinations; ethambutol not specifically mentioned).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.jeong.2015.167">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Jeong</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>JS</given-names>
                </name>
                <name name-style="western">
                  <surname>Cho</surname>
                  <given-names>YJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Yoon</surname>
                  <given-names>HI</given-names>
                </name>
                <name name-style="western">
                  <surname>Song</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>CT</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>JH</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.</article-title>
              <source>J Korean Med Sci</source>
              <year>2015</year>
              <volume>30</volume>
              <fpage>167</fpage>
              <lpage>72</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 195 Korean patients with tuberculosis treated with a 4-drug regimen of isoniazid, rifampin, ethambutol and pyrazinamide, drug levels taken within the first week of treatment did not correlate with subsequent rate or severity of antituberculosis drug induced liver injury [n=12: 6%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25653488</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.horita.2015.2315">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Horita</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Miyazawa</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Yoshiyama</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Kojima</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Ishigatsubo</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Kaneko</surname>
                  <given-names>T</given-names>
                </name>
              </person-group>
              <article-title>Currently used low-dose pyrazinamide does not increase liver-injury in the first two months of tuberculosis treatment.</article-title>
              <source>Intern Med</source>
              <year>2015</year>
              <volume>54</volume>
              <fpage>2315</fpage>
              <lpage>20</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 383 Chinese patients with tuberculosis treated with isoniazid, rifampin and ethambutol with or without pyrazinamide analyzed in a retrospective study, liver injury arising within the first two months of therapy was less frequent with four drug [8%] than 3-drug regimen [24%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">26370854</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 54 [6%] were attributed to antituberculosis agents including 48 to isoniazid, 2 to rifampin, 2 to pyrazinamide, 1 to ethambutol and 1 to isoniazid and rifampin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.sharma.2015.8">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sharma</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Tyagi</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Singla</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Bansal</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Kumar</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Arora</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis.</article-title>
              <source>J Clin Exp Hepatol</source>
              <year>2015</year>
              <volume>5</volume>
              <fpage>8</fpage>
              <lpage>13</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 67 patients with cirrhosis treated for tuberculosis with isoniazid, rifampin, ethambutol and either ofloxacin or pyrazinamide, evidence of drug induced liver injury arose in 35% of cases, but none were attributed to ethambutol or pyrazinamide and there were no deaths attributed to drug toxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25941429</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.golemba.2015.e6135">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Golemba</surname>
                  <given-names>AS</given-names>
                </name>
                <name name-style="western">
                  <surname>Ferreyra</surname>
                  <given-names>FG</given-names>
                </name>
                <name name-style="western">
                  <surname>Martearena</surname>
                  <given-names>RE</given-names>
                </name>
                <name name-style="western">
                  <surname>Achinelli</surname>
                  <given-names>FR</given-names>
                </name>
                <name name-style="western">
                  <surname>Rovai</surname>
                  <given-names>GB</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced hepatotoxicity and tuberculosis in a hospital from the Argentinian northeast: cross-sectional study.</article-title>
              <source>Medwave</source>
              <year>2015</year>
              <volume>15</volume>
              <elocation-id>e6135</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 118 patients with tuberculosis treated with isoniazid, rifampin and ethambutol between 2011 and 2014, 9 (8%) developed hepatotoxicity, but only two had jaundice and none died or underwent transplantation).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">26035138</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.blair.2015.bcr2015210907">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Blair</surname>
                  <given-names>PW</given-names>
                </name>
                <name name-style="western">
                  <surname>Herrin</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Abaalkhail</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fiser</surname>
                  <given-names>W</given-names>
                </name>
              </person-group>
              <article-title>DRESS syndrome presenting after initiation of mycobacterium avium complex osteomyelitis treatment.</article-title>
              <source>BMJ Case Rep</source>
              <year>2015</year>
              <volume>2015</volume>
              <elocation-id>bcr2015210907</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(79 year old man developed rash, fever and eosinophilia 4 weeks after starting isoniazid, rifampin, ethambutol and clarithromycin for MAC osteomyelitis [ALT 56 rising to 86 U/L, bilirubin and Alk P not provided] which did not improve upon stopping the medications but did once high dose corticosteroids were begun; no follow up on rechallenge or outcome of osteomyelitis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">26438676</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.choi.2016.267">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Choi</surname>
                  <given-names>JH</given-names>
                </name>
                <name name-style="western">
                  <surname>Heo</surname>
                  <given-names>NY</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>SH</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>CS</given-names>
                </name>
                <name name-style="western">
                  <surname>Jo</surname>
                  <given-names>KM</given-names>
                </name>
                <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>WG</given-names>
                </name>
                <name name-style="western">
                  <surname>Nam</surname>
                  <given-names>KH</given-names>
                </name>
              </person-group>
              <comment>[Concomitant drug reaction with eosinophilia and systemic symptom syndrome from ethambutol and autoimmune hepatitis from isoniazid]</comment>
              <source>Korean J Gastroenterol</source>
              <year>2016</year>
              <volume>67</volume>
              <fpage>267</fpage>
              <lpage>71</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Woman with tuberculosis developed fever, rash and eosinophilia within 2 months of starting combination therapy with isoniazid, rifampin, ethambutol and pyrazinamide [ALT rising to 650 U/L], responding to prednisone therapy and fever and rash recurring with reintroduction of ethambutol).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">27206439</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.usui.2016.1793">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Usui</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Whitaker</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Meng</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Watson</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Antoine</surname>
                  <given-names>DJ</given-names>
                </name>
                <name name-style="western">
                  <surname>French</surname>
                  <given-names>NS</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>BK</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Detection of drug-responsive T-lymphocytes in a case of fatal antituberculosis drug-related liver injury.</article-title>
              <source>Chem Res Toxicol</source>
              <year>2016</year>
              <volume>29</volume>
              <fpage>1793</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(50 year old man developed liver injury 3 weeks after starting combination therapy for tuberculosis [peak bilirubin 32 mg/dL, ALT 2373 U/L, INR 4.4], dying within a month of onset; cloning of T cells taken early in the course revealed reactivity to ethambutol and rifampin but not isoniazid and pyrazinamide).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">27933861</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.wang.2016.334">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>FJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Niu</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Lu</surname>
                  <given-names>WX</given-names>
                </name>
                <name name-style="western">
                  <surname>Sandford</surname>
                  <given-names>AJ</given-names>
                </name>
                <name name-style="western">
                  <surname>He</surname>
                  <given-names>JQ</given-names>
                </name>
              </person-group>
              <article-title>Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies.</article-title>
              <source>J Clin Pharm Ther</source>
              <year>2016</year>
              <volume>41</volume>
              <fpage>334</fpage>
              <lpage>40</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Metaanalysis of 26 studies involving 7423 patients found that the CYP2E1 RsaI/PstI c1/c1 polymorphism was associated with an increased risk for liver injury caused by antituberculosis therapy with an odds ratio of 1.32).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">27062377</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.allouchery.2018.1373">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Allouchery</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Logerot</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Cottin</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Pralong</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Villier</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Ben Sa&#x000ef;d</surname>
                  <given-names>B</given-names>
                </name>
              </person-group>
              <article-title>French Pharmacovigilance Centers Network and the French Investigators for skin adverse reactions to drugs. Antituberculosis drug-associated DRESS: a case series.</article-title>
              <source>J Allergy Clin Immunol Pract</source>
              <year>2018</year>
              <volume>6</volume>
              <fpage>1373</fpage>
              <lpage>80</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 67 cases of DRESS syndrome attributed to antituberculosis medications reported to a French pharmacovigilance registry between 2005 and 2015, there were 40 women and 27 men, median age of 61 years and the most commonly implicated agents were isoniazid and rifampin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29274824</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.tweed.2018.46">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Tweed</surname>
                  <given-names>CD</given-names>
                </name>
                <name name-style="western">
                  <surname>Wills</surname>
                  <given-names>GH</given-names>
                </name>
                <name name-style="western">
                  <surname>Crook</surname>
                  <given-names>AM</given-names>
                </name>
                <name name-style="western">
                  <surname>Dawson</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Diacon</surname>
                  <given-names>AH</given-names>
                </name>
                <name name-style="western">
                  <surname>Louw</surname>
                  <given-names>CE</given-names>
                </name>
                <name name-style="western">
                  <surname>McHugh</surname>
                  <given-names>TD</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.</article-title>
              <source>BMC Med</source>
              <year>2018</year>
              <volume>16</volume>
              <fpage>46</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1928 patients with pulmonary tuberculosis treated with ethambutol,&#x000a0;isoniazid, rifampin and pyrazinamide or regimens in which moxifloxacin was substituted for either ethambutol or&#x000a0;isoniazid, liver injury arose in 58 patients [3%] overall, and was less with regimen in which moxifloxacin replaced&#x000a0;isoniazid&#x000a0;[2.2%], but there was nevertheless a liver related death on this regimen).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29592805</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.kapur.2019.249">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kapur</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Rehan</surname>
                  <given-names>HS</given-names>
                </name>
              </person-group>
              <article-title>Drug reaction with eosinophilia and systemic symptoms syndrome associated with ethambutol use: a case report.</article-title>
              <source>Curr Drug Saf</source>
              <year>2019</year>
              <volume>14</volume>
              <fpage>249</fpage>
              <lpage>51</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(34 year old woman developed fever, rash and eosinophilia 35 days after starting antituberculosis therapy with isoniazid, rifampin, pyrazinamide, ethambutol and streptomycin that responded to stopping therapy and systemic corticosteroids, but rapidly recurred upon restarting ethambutol alone and she later tolerated the other agents).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30848209</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.hagiwara.2019.1026">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hagiwara</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Suido</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Asaoka</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Katano</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Okuda</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Sekine</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Kitamura</surname>
                  <given-names>H</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.</article-title>
              <source>J Infect Chemother</source>
              <year>2019</year>
              <volume>25</volume>
              <fpage>1026</fpage>
              <lpage>30</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 89 elderly patients [80 years or older] with tuberculosis treated with isoniazid, rifampin and ethambutol with or without pyrazinamide, rates of discontinuation were similar between the two groups [33% vs 35%] as well as rates of ALT or AST elevations above 2.5 times ULN [18% vs 23%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31229376</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.wang.2019.2217">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Xiang</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Huang</surname>
                  <given-names>WW</given-names>
                </name>
                <name name-style="western">
                  <surname>Sandford</surname>
                  <given-names>AJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Wu</surname>
                  <given-names>SQ</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>MM</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>MG</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Association of PXR and CAR polymorphisms and antituberculosis drug-induced hepatotoxicity.</article-title>
              <source>Sci Rep</source>
              <year>2019</year>
              <volume>9</volume>
              <fpage>2217</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 502 patients with tuberculosis treated with isoniazid, rifampin, ethambutol and pyrazinamide 19% developed ALT elevations above 10 times ULN, several polymorphisms of PXR [but not CAR] were associated with a lower incidence of liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30778091</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.dheda.2019.820">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dheda</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Gumbo</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Maartens</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Dooley</surname>
                  <given-names>KE</given-names>
                </name>
                <name name-style="western">
                  <surname>Murray</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Furin</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Nardell</surname>
                  <given-names>EA</given-names>
                </name>
                <name name-style="western">
                  <surname>Warren</surname>
                  <given-names>RM</given-names>
                </name>
              </person-group>
              <article-title>Lancet Respiratory Medicine drug-resistant tuberculosis Commission group. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.</article-title>
              <source>Lancet Respir Med</source>
              <year>2019</year>
              <volume>7</volume>
              <fpage>820</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the epidemiology, pathogenesis, diagnosis and management of multidrug resistant tuberculosis; does not discuss hepatotoxicity of therapeutic drug regimens).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31486393</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.beauglehole.2020.1431">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Beauglehole</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Nolan</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Italiano</surname>
                  <given-names>CM</given-names>
                </name>
              </person-group>
              <article-title>Acute liver failure likely due to ethambutol in the treatment of AIDS-associated disseminated Mycobacterium avium complex infection.</article-title>
              <source>Intern Med J</source>
              <year>2020</year>
              <volume>50</volume>
              <fpage>1431</fpage>
              <lpage>2</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(34 year old man with HIV infection and Mycobacterium avium complex [MAC] infection developed cholestatic liver injury with jaundice [bilirubin ~12 mg/dL] within 4 weeks of starting isoniazid, pyrazinamide, clarithromycin, rifabutin and ethambutol and had recurrence 3 times with reinstitution of MAC therapy, eventually resolving only when switching to an ethambutol-free regimen).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">33215828</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.zhao.2020.e920350">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Zhao</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Wang</surname>
                  <given-names>Q</given-names>
                </name>
                <name name-style="western">
                  <surname>Xie</surname>
                  <given-names>W</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced liver injury from anti-tuberculosis treatment: a retrospective cohort study.</article-title>
              <source>Med Sci Monit</source>
              <year>2020</year>
              <volume>26</volume>
              <elocation-id>e920350</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 140 patients with liver injury due to antituberculosis therapy seen between 2009 and 2015, the median age was 40, time to onset ranged from 7-90 days [mean=24], 35% had fever, 16% rash, 68% were hepatocellular, 21% were severe and 7% died; most patients had received isoniazid, rifampin and pyrazinamide).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">32145061</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.soni.2020.171">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Soni</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Kumar-M</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Mishra</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Bellam</surname>
                  <given-names>BL</given-names>
                </name>
                <name name-style="western">
                  <surname>Singh</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Mandavdhare</surname>
                  <given-names>HS</given-names>
                </name>
                <name name-style="western">
                  <surname>Medhi</surname>
                  <given-names>B</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Risk of hepatitis with various reintroduction regimens of anti-tubercular therapy: a systematic review and network meta-analysis.</article-title>
              <source>Expert Rev Anti Infect Ther</source>
              <year>2020</year>
              <volume>18</volume>
              <fpage>171</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of the risk of recurrence of hepatotoxicity on reintroduction of antituberculosis agents after occurrence of drug induced liver injury indicated that sequential and incremental introduction is preferable to rechallenge with full doses of both agents concurrently).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31923369</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.gezahegn.2020.e0241346">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Gezahegn</surname>
                  <given-names>LK</given-names>
                </name>
                <name name-style="western">
                  <surname>Argaw</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Assefa</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Geberesilassie</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Hagazi</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North Ethiopia: A cross-sectional study.</article-title>
              <source>PLoS One</source>
              <year>2020</year>
              <volume>15</volume>
              <elocation-id>e0241346</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 188 patients treated for tuberculosis with isoniazid, rifampin, pyrazinamide and ethambutol in a single referral center in Ethiopia over a 3 year period, 26 [14%] developed evidence of drug induced liver injury including 3 who died).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">33170847</pub-id>
            </element-citation>
          </ref>
          <ref id="Ethambutol.REF.cdc">
            <mixed-citation publication-type="web"><person-group><collab>CDC</collab></person-group>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/tb/">https://www.cdc.gov/tb/</ext-link><annotation><p><italic toggle="yes">(CDC website with up-to-date recommendations on therapy of tuberculosis).</italic></p></annotation></mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Ethambutol.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Ethambutol/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Ethambutol: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Ethambutol">Trials on Ethambutol: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
